

# Christopher G Morris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10551732/publications.pdf>

Version: 2024-02-01

190  
papers

8,177  
citations

34105  
52  
h-index

54911  
84  
g-index

192  
all docs

192  
docs citations

192  
times ranked

7719  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insurance Approval for Definitive Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2022, 8, 36-42.	1.8	3
2	Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 21-27.	1.8	0
3	Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients. International Journal of Particle Therapy, 2022, 8, 28-35.	1.8	2
4	Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: An Update of the University of Florida Experience. International Journal of Radiation Oncology Biology Physics, 2022, 113, 161-165.	0.8	2
5	Postoperative Radiotherapy for Cutaneous Melanoma in Patients at High Risk of Local-Regional Recurrence after Surgery Alone. Cancer Investigation, 2022, , 1-6.	1.3	0
6	Modern Therapy for Chest Wall Ewing Sarcoma: An Update of the XXX Experience. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	3
7	Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 732-741.	0.8	5
8	Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series. Journal of Neuro-Oncology, 2022, 157, 425-433.	2.9	7
9	Adjuvant I-131 therapy for T0â€“3 N1b M0 differentiated thyroid cancer with many (â‰¥ 5) positive nodes. Reports of Practical Oncology and Radiotherapy, 2022, 27, 121-124.	0.6	0
10	Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. Acta Oncologica, 2022, 61, 468-477.	1.8	1
11	A Prospective Randomized Trial of the Influence of Music on Anxiety in Patients Starting Radiation Therapy for Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 670-674.	0.8	15
12	Outcomes following limited-volume proton therapy for multifocal spinal myxopapillary ependymoma. Pediatric Blood and Cancer, 2021, 68, e28820.	1.5	3
13	Local Control After Proton Therapy for Pediatric Chordoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1406-1413.	0.8	10
14	Second tumor risk in children treated with proton therapy. Pediatric Blood and Cancer, 2021, 68, e28941.	1.5	23
15	Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. International Journal of Particle Therapy, 2021, 7, 52-64.	1.8	0
16	Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma. Radiotherapy and Oncology, 2021, 158, 125-130.	0.6	12
17	Long-term Outcomes from Proton Therapy for Sinonasal Cancers. International Journal of Particle Therapy, 2021, 8, 200-212.	1.8	6
18	Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes. Journal of Neuro-Oncology, 2021, 153, 467-476.	2.9	5

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes Following Dose-Escalated Proton Therapy for Skull-Base Chordoma. International Journal of Particle Therapy, 2021, 8, 179-188.	1.8	9
20	Proton Therapy for Pediatric Ependymoma: Mature Results From a Bicentric Study. International Journal of Radiation Oncology Biology Physics, 2021, 110, 815-820.	0.8	27
21	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. Clinical and Translational Science, 2021, 14, 2314-2326.	3.1	4
22	Sparing the Larynx and Hypopharynx With Radiation Therapy for Squamous Cell Carcinoma of Unknown Primary Site and Predominant Adenopathy in Level IIA. Practical Radiation Oncology, 2021, 11, 366-373.	2.1	1
23	Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor. Radiotherapy and Oncology, 2021, 163, 215-220.	0.6	4
24	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	2.1	51
25	Radiation treatment of soft palate squamous cell carcinoma. Head and Neck, 2020, 42, 530-538.	2.0	5
26	Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base. Pediatric Blood and Cancer, 2020, 67, e28080.	1.5	15
27	Visual decline in pediatric survivors of brain tumors following radiotherapy. Acta Oncol <sup>3</sup> gica, 2020, 59, 1257-1262.	1.8	5
28	Curative-intent radiotherapy for glottic carcinoma in situ. Head and Neck, 2020, 42, 3515-3517.	2.0	1
29	Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer. Acta Oncol <sup>3</sup> gica, 2020, 59, 1164-1170.	1.8	6
30	Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529.	0.8	2
31	Patterns of Failure in Parameningeal Alveolar Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 325-333.	0.8	11
32	Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2020, 106, 968-976.	0.8	13
33	Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. International Journal of Radiation Oncology Biology Physics, 2020, 107, 455-461.	0.8	21
34	Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis. International Journal of Radiation Oncology Biology Physics, 2020, 107, 974-981.	0.8	22
35	Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study. International Journal of Particle Therapy, 2020, 7, 1-10.	1.8	6
36	Risk Factors Impacting Operative Mortality and Overall Survival in Adults Treated for Skull Base Chordoma and Chondrosarcoma. , 2020, 81, .		0

#	ARTICLE	IF	CITATIONS
37	Circulating Cell-Free DNA Correlates with Body Integral Dose and Radiation Modality in Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2020, 7, 21-30.	1.8	1
38	Comparison of Techniques for Involved-Site Radiation Therapy in Patients With Lower Mediastinal Lymphoma. <i>Practical Radiation Oncology</i> , 2019, 9, 426-434.	2.1	22
39	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. <i>Radiotherapy and Oncology</i> , 2019, 138, 75-79.	0.6	11
40	Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors. <i>Advances in Radiation Oncology</i> , 2019, 4, 699-705.	1.2	9
41	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. <i>Acta Oncologica</i> , 2019, 58, 313-319.	1.8	2
42	Radiation-induced tumor immunity in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1605-1611.	1.9	9
43	Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status. <i>Radiotherapy and Oncology</i> , 2019, 140, 6-9.	0.6	17
44	Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 500-506.	1.2	11
45	Challenging the concept that late recurrence and death from tumor are common after fractionated radiotherapy for benign meningioma. <i>Radiotherapy and Oncology</i> , 2019, 137, 55-60.	0.6	5
46	Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. <i>Cancer Investigation</i> , 2019, 37, 85-89.	1.3	5
47	Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. <i>Journal of Neuro-Oncology</i> , 2019, 142, 557-563.	2.9	41
48	Isolated leptomeningeal progression from sinonasal carcinomas: Implications for staging workup and treatment. <i>Head and Neck</i> , 2019, 41, 2647-2654.	2.0	6
49	Outcomes Following Proton Therapy for Pediatric Low-Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 149-156.	0.8	86
50	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 204-210.	0.6	5
51	Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single-institution outcomes. <i>Head and Neck</i> , 2019, 41, 2309-2314.	2.0	37
52	Radiotherapy for benign head and neck paragangliomas. <i>Head and Neck</i> , 2019, 41, 2107-2110.	2.0	9
53	Risk of Radiation Vasculopathy and Stroke in Pediatric Patients Treated With Proton Therapy for Brain and Skull Base Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 854-859.	0.8	32
54	Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27006.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2018, 57, 582-588.	1.8	17
56	Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26997.	1.5	11
57	Radiation Therapy for Aggressive Fibromatosis: The Association Between Local Control and Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 997-1003.	0.8	23
58	Outcomes following proton therapy for pediatric ependymoma. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2018, 57, 644-648.	1.8	51
59	Radiotherapy in the Management of Orbital Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 100-106.	1.3	14
60	Long-term Outcomes After Radiosurgery for Temporal Bone Paragangliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 223-226.	1.3	16
61	Radiotherapy Alone or With Chemotherapy in the Management of Carcinoma of the Supraglottic Larynx. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 894-897.	1.3	1
62	Management of cutaneous Merkel cell carcinoma. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2018, 57, 320-323.	1.8	5
63	Proton therapy in stage IIâ€“IV non-small cell lung cancer: pattern of care and impact on trial accrual. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2018, 57, 692-693.	1.8	5
64	Patterns of Failure in Patients With Adult Medulloblastoma Presenting Without Extraneural Metastasis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1015-1018.	1.3	10
65	Innenr <sup>1</sup> / <sub>4</sub> cktitelbild: Ammonia Storage by Reversible Hostâ€“Guest Site Exchange in a Robust Metalâ€“Organic Framework ( <i>Angew. Chem.</i> 45/2018). <i>Angewandte Chemie</i> , 2018, 130, 15163-15163.	2.0	0
66	Radiotherapy for Orbital Pseudotumor: The University of Florida Experience. <i>Cancer Investigation</i> , 2018, 36, 330-337.	1.3	7
67	Ammonia Storage by Reversible Hostâ€“Guest Site Exchange in a Robust Metalâ€“Organic Framework. <i>Angewandte Chemie</i> , 2018, 130, 14994-14997.	2.0	14
68	Lingual Tonsillectomy Likely Does Not Improve Outcomes for Squamous Cell Carcinoma of the Head and Neck From an Unknown Primary Site. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1216-1219.	1.3	4
69	Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose. <i>Cancer Investigation</i> , 2018, 36, 289-295.	1.3	1
70	A Prospective Outcomes Study of Proton Therapy for Skull-Base Chondrosarcomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.8	0
71	Adjuvant postoperative radiotherapy for cutaneous melanoma. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2017, 56, 495-496.	1.8	5
72	Radiotherapy alone or combined with chemotherapy for base of tongue squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1589-1594.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Metal-organic frameworks in seconds via selective microwave heating. <i>Journal of Materials Chemistry A</i> , 2017, 5, 7333-7338.	10.3	71
74	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 197-203.	1.2	11
75	Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma. <i>Acta Oncologica</i> , 2017, 56, 484-489.	1.8	24
76	Primary Management of Squamous Cell Carcinoma of the Anal Canal: A 30-year Community Hospital Experience. <i>Cancer Investigation</i> , 2017, 35, 547-551.	1.3	2
77	Sperm preservation and neutron contamination following proton therapy for prostate cancer study. <i>Acta Oncologica</i> , 2017, 56, 17-20.	1.8	6
78	Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2017, 9, 103.	1.5	13
79	Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. <i>International Journal of Particle Therapy</i> , 2017, 3, 461-472.	1.8	2
80	Evaluating Cardiac Biomarkers after Chemotherapy and Proton Therapy for Mediastinal Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2017, 4, 35-38.	1.8	4
81	Proton Therapy for Pediatric Hodgkin Lymphoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1522-1526.	1.5	20
82	Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 411-421.	0.8	93
83	Proton Conduction in a Phosphonate-Based Metal-Organic Framework Mediated by Intrinsic Free Diffusion inside a Sphere. <i>Journal of the American Chemical Society</i> , 2016, 138, 6352-6355.	13.7	186
84	Outcomes of Sinonasal Cancer Treated With Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 377-385.	0.8	61
85	A Prospective Outcomes Study of Proton Therapy for Chordomas and Chondrosarcomas of the Spine. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 297-303.	0.8	88
86	Elective neck management for squamous cell carcinoma metastatic to the parotid area lymph nodes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3875-3879.	1.6	17
87	Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2117-2125.	1.6	7
88	Reducing Anesthesia and Health Care Cost Through Utilization of Child Life Specialists in Pediatric Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 401-405.	0.8	51
89	Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 261-265.	1.3	7
90	Challenging the need for random directed biopsies of the nasopharynx, pyriform sinus, and contralateral tonsil in the workup of unknown primary squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 578-581.	2.0	26

#	ARTICLE	IF	CITATIONS
91	Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. International Journal of Radiation Oncology Biology Physics, 2016, 95, 465-471.	0.8	9
92	Primary radiotherapy for squamous cell carcinoma of the pyriform sinus. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1857-1862.	1.6	6
93	Ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2151-2156.	1.6	24
94	Radiation therapy for nasal vestibule squamous cell carcinoma: a 40-year experience. European Archives of Oto-Rhino-Laryngology, 2016, 273, 661-669.	1.6	26
95	Thirty-day mortality rate in oncology patients treated with palliative radiotherapy.. Journal of Clinical Oncology, 2016, 34, 172-172.	1.6	3
96	Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. Radiation Oncology, 2015, 10, 199.	2.7	16
97	Impact of Radiographic Findings on For Prognosis Skin Cancer With Perineural Invasion. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 248-251.	1.3	24
98	Retromolar trigone squamous cell carcinoma treated with radiotherapy alone or combined with surgery: a 10-year update. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 140-145.	1.3	13
99	External-beam radiation therapy for malignant paraganglioma of the head and neck. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 692-696.	1.3	18
100	Radiation Therapy for Mucosal Melanoma of the Head and Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 87-89.	1.3	47
101	Implementing an Electronic Event-Reporting System in a Radiation Oncology Department: The Effect on Safety Culture and Near-Miss Prevention. Journal of the American College of Radiology, 2015, 12, 1191-1195.	1.8	11
102	Local control in non-metastatic medulloblastoma. Acta Oncol <sup>3</sup> gica, 2014, 53, 1151-1157.	1.8	6
103	Angiosarcoma after breast-conserving therapy: Long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol <sup>3</sup> gica, 2014, 53, 235-241.	1.8	31
104	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer, 2014, 120, 1076-1082.	4.1	82
105	Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta Oncol <sup>3</sup> gica, 2014, 53, 471-480.	1.8	58
106	Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy. Acta Oncol <sup>3</sup> gica, 2014, 53, 1298-1304.	1.8	180
107	Radiotherapy Alone or Combined With Chemotherapy for the Treatment of Squamous Cell Carcinoma of the Base of the Tongue. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 535-538.	1.3	4
108	Radiotherapy for Dermatofibrosarcoma Protuberans. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 430-432.	1.3	39



#	ARTICLE	IF	CITATIONS
109	Radiotherapy for sinonasal undifferentiated carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 141-146.	1.3	24
110	Radiotherapy for benign head and neck paragangliomas: A 45-year experience. Cancer, 2014, 120, 3738-3743.	4.1	93
111	Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 596-602.	0.8	103
112	Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1053-1059.	0.8	60
113	Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. International Journal of Particle Therapy, 2014, 1, 692-701.	1.8	38
114	Patient-reported sexual outcomes and potency following proton therapy for the management of prostate cancer.. Journal of Clinical Oncology, 2014, 32, 160-160.	1.6	0
115	First report of a prospective trial of proton therapy and concomitant capecitabine for patients with nonmetastatic unresectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, e15223-e15223.	1.6	0
116	Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 3-8.	1.4	56
117	Elective neck management for high-grade salivary gland carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2013, 34, 205-208.	1.3	57
118	Radiation therapy for sinonasal inverted papilloma. Practical Radiation Oncology, 2013, 3, 275-281.	2.1	10
119	Mohs resection and postoperative radiotherapy for head and neck cancers with incidental perineural invasion. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2013, 34, 373-377.	1.3	38
120	Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. Acta Oncologica, 2013, 52, 463-469.	1.8	17
121	Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncologica, 2013, 52, 498-505.	1.8	66
122	Radiation Therapy for Angiosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 174-180.	1.3	41
123	Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 213-221.	0.8	95
124	Multimodality Local Therapy for Retroperitoneal Sarcoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1128-1134.	0.8	34
125	Comparison of Three-Dimensional (3D) Conformal Proton Radiotherapy (RT), 3D Conformal Photon RT, and Intensity-Modulated RT for Retroperitoneal and Intra-Abdominal Sarcomas. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1549-1557.	0.8	62
126	Definitive radiation therapy for squamous cell carcinoma of the pharyngeal wall. Practical Radiation Oncology, 2012, 2, e113-e119.	2.1	2



#	ARTICLE	IF	CITATIONS
127	Radiotherapy following gross total resection of adult soft tissue sarcoma of the head and neck. Practical Radiation Oncology, 2012, 2, e121-e128.	2.1	10
128	Cutaneous Merkel cell carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 88-92.	1.3	13
129	Skin carcinoma of the head and neck with perineural invasion. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 447-454.	1.3	96
130	Adenoid cystic carcinoma of the head and neck. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2012, 33, 510-518.	1.3	102
131	Radiation therapy for squamous cell carcinoma of the subglottic larynx. Journal of Radiation Oncology, 2012, 1, 333-336.	0.7	3
132	The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity. Cancer, 2012, 118, 3199-3207.	4.1	81
133	Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer, 2012, 118, 4619-4626.	4.1	51
134	Head and neck squamous cell carcinoma from an unknown primary site. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2011, 32, 286-290.	1.3	73
135	Favorable Outcomes of Pediatric Patients Treated With Radiotherapy to the Central Nervous System Who Develop Radiation-Induced Meningiomas. International Journal of Radiation Oncology Biology Physics, 2011, 79, 117-120.	0.8	36
136	Outcomes of WHO Grade I Meningiomas Receiving Definitive or Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 508-513.	0.8	53
137	Radiation Therapy for Management of T1-T2 Glottic Cancer at a Private Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 587-590.	1.3	32
138	Angiosarcoma after breast-conserving therapy. Cancer, 2010, 116, 1872-1878.	4.1	69
139	Elective neck dissection during salvage surgery for locally recurrent head and neck squamous cell carcinoma after radiotherapy with elective nodal irradiation. Laryngoscope, 2010, 120, 945-952.	2.0	41
140	Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma1. Laryngoscope, 2010, 120, 2218-2222.	2.0	60
141	Carotid-Sparing Intensity-Modulated Radiotherapy for Early-Stage Squamous Cell Carcinoma of the True Vocal Cord. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1380-1385.	0.8	82
142	T1N0 to T2N0 Squamous Cell Carcinoma of the Glottic Larynx Treated With Definitive Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 461-466.	0.8	150
143	Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 425-430.	0.6	63
144	Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope, 2009, 119, 899-906.	2.0	78

#	ARTICLE	IF	CITATIONS
145	Radiation therapy for minor salivary gland carcinoma. <i>Laryngoscope</i> , 2009, 119, 1334-1338.	2.0	39
146	Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. <i>Laryngoscope</i> , 2009, 119, 2348-2354.	2.0	201
147	Dosimetric Comparison of Three Different Involved Nodal Irradiation Techniques for Stage II Hodgkin's Lymphoma Patients: Conventional Radiotherapy, Intensity-Modulated Radiotherapy, and Three-Dimensional Proton Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1173-1180.	0.8	113
148	Definitive Altered Fractionation Radiotherapy and Concomitant Weekly Cisplatin for Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 488-491.	1.3	7
149	Xerostomia in Long-term Survivors of Aggressive Non-Hodgkin's Lymphoma of Waldeyer's Ring. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 145-149.	1.3	12
150	Lymph node–positive head and neck cancer treated with definitive radiotherapy. <i>Cancer</i> , 2008, 112, 1076-1082.	4.1	55
151	Definitive radiation therapy for squamous cell carcinoma of the soft palate. <i>Head and Neck</i> , 2008, 30, 1114-1119.	2.0	22
152	Definitive radiotherapy in the management of paragangliomas arising in the head and neck: A 35–year experience. <i>Head and Neck</i> , 2008, 30, 1431-1438.	2.0	129
153	Patterns of Failure and Toxicity after Intensity-Modulated Radiotherapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 377-385.	0.8	146
154	Definitive Radiotherapy for T1-T2 Squamous Cell Carcinoma of Pyriform Sinus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 351-355.	0.8	44
155	Definitive Radiotherapy for Ewing Tumors of Extremities and Pelvis: Long-Term Disease Control, Limb Function, and Treatment Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 871-877.	0.8	50
156	Cutaneous Squamous Cell Carcinoma Metastatic to Parotid–Area Lymph Nodes. <i>Laryngoscope</i> , 2008, 118, 1989-1996.	2.0	94
157	Mucosal Melanoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 43-48.	1.3	71
158	T3 and T4 True Vocal Cord Squamous Carcinomas Treated With External Beam Irradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 181-185.	1.3	51
159	Prognostic Significance of Paraglottic Space Invasion in T2N0 Glottic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 186-190.	1.3	31
160	Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: Salvage in the dissected or undissected neck. <i>Head and Neck</i> , 2007, 29, 715-719.	2.0	28
161	Postradiotherapy Neck Dissection for Lymph Node–Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 1421-1427.	1.6	160
162	Definitive Radiotherapy for Nasopharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 622-627.	1.3	18

#	ARTICLE	IF	CITATIONS
163	Definitive Radiotherapy for Squamous Cell Carcinoma of the Base of Tongue. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 32-39.	1.3	51
164	Definitive Radiotherapy for Tonsillar Squamous Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 290-297.	1.3	93
165	Hypothyroidism When the Thyroid Is Included Only in the Low Neck Field During Head and Neck Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 442-445.	1.3	39
166	Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: Incomplete radiographic response does not necessarily indicate failure. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1017-1021.	0.8	6
167	Larynx-Sparing Radiotherapy for Squamous Cell Carcinoma From an Unknown Head and Neck Primary Site. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 445-448.	1.3	37
168	Adjuvant Radiation Therapy for Resectable Retroperitoneal Soft Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 310-316.	1.3	111
169	Aggressive Fibromatosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 211-215.	1.3	75
170	Late Xerostomia After Intensity-Modulated Radiation Therapy Versus Conventional Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 351-358.	1.3	73
171	Thyroid Function Should Be Monitored Following Radiotherapy to the Low Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 255-258.	1.3	84
172	Pushing the Limits of Radiotherapy for Atypical and Malignant Meningioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 70-74.	1.3	54
173	Radiotherapy in the Treatment of Dermatofibrosarcoma Protuberans. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 537-539.	1.3	90
174	Preventing radiation retinopathy with hyperfractionation. International Journal of Radiation Oncology Biology Physics, 2005, 61, 856-864.	0.8	110
175	Does altered fractionation influence the risk of radiation-induced optic neuropathy?. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1070-1077.	0.8	118
176	Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion. Cancer, 2005, 103, 1254-1257.	4.1	93
177	Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer, 2005, 103, 2544-2550.	4.1	189
178	Merkel cell carcinoma. Cancer, 2005, 104, 1761-1764.	4.1	92
179	Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head and Neck, 2004, 26, 154-162.	2.0	284
180	Definitive radiotherapy alone or combined with a planned neck dissection for squamous cell carcinoma of the pharyngeal wall. Cancer, 2003, 98, 2224-2231.	4.1	22

#	ARTICLE	IF	CITATIONS
181	Impact of race on outcome after definitive radiotherapy for squamous cell carcinoma of the head and neck. Cancer, 2003, 98, 2467-2472.	4.1	29
182	Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head and Neck, 2003, 25, 535-542.	2.0	72
183	Distant metastases after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head and Neck, 2003, 25, 629-633.	2.0	45
184	Does feeding tube placement predict for long-term swallowing disability after radiotherapy for head and neck cancer?. Head and Neck, 2003, 25, 741-747.	2.0	46
185	Carcinoma of the skin with perineural invasion. Head and Neck, 2003, 25, 1027-1033.	2.0	170
186	Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation Therapy. JAMA - Journal of the American Medical Association, 2003, 290, 2831.	7.4	556
187	Voice Rehabilitation After Total Laryngectomy and Postoperative Radiation Therapy. Journal of Clinical Oncology, 2002, 20, 2500-2505.	1.6	54
188	T1-T2N0 Squamous Cell Carcinoma of the Glottic Larynx Treated With Radiation Therapy. Journal of Clinical Oncology, 2001, 19, 4029-4036.	1.6	303
189	Local excision and postoperative radiation therapy for rectal adenocarcinoma. International Journal of Cancer, 2001, 96, 89.	5.1	30
190	Impact of Type of Treatment Center and Access to Care on Mortality and Survival for Skull Base Chordoma and Chondrosarcoma. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.8	3